NDAINJECTIONINJECTABLE
Approved
Jul 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NICARDIPINE HYDROCHLORIDE (nicardipine hydrochloride) by Hikma is concentrations. First approved in 2008.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Nicardipine hydrochloride is a dihydropyridine calcium channel blocker administered via injection for acute management of hypertension and angina. It selectively relaxes vascular smooth muscle by inhibiting extracellular calcium influx, producing vasodilation with minimal negative inotropic effects on cardiac muscle.
LOE Approaching
With LOE approaching, the product team is likely contracting and shifting focus toward niche positioning or transition planning in acute care markets.
Mechanism of Action
concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on nicardipine positions you in the acute care/hospital channel with strong clinical engagement requirements and emphasis on provider education in emergency and OR settings. The LOE trajectory means limited growth potential on the brand itself, but valuable experience in managed decline and niche market defense strategies.
Hospital Sales Specialist
Worked on NICARDIPINE HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.